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 Abstract 
 
Background: Vascular calcification accompanying chronic kidney disease (CKD) increases 
the mortality and morbidity associated with cardiovascular disorders, but no effective therapy 
is available. We hypothesized that glycosaminoglycans (GAG) may contribute to osteoblastic 
differentiation of vascular smooth muscle cells (VSMCs) during vascular calcification.  
Methods and Results: We used exostosin-like glycosyltranferase 2 deficient (EXTL2 KO) 
mice expressing high levels of GAG in several organs including the aorta. We performed 5/6 
subtotal nephrectomy and fed the mice a high-phosphate diet to induce CKD. Overexpression 
of GAG in the aorta enhanced aortic calcification in CKD in EXTL2 KO mice. Ex vivo and 
in vitro, matrix mineralization in aortic rings and VSMCs of EXTL2 KO mice was 
augmented. Furthermore, removal of GAG in EXTL2 KO and WT mice-derived VSMCs 
effectively suppressed calcium deposition in a high-phosphate environment. 
Conclusions: These results illustrate an important role for GAG in the development of 
vascular calcification. Manipulation of GAG expression may have beneficial effects on the 
progression of vascular calcification in CKD patients. 
 
Keywords: Vascular calcification, Chronic Kidney Disease, Glycosaminoglycan, Heparan 
Sulfate, Chondroitin Sulfate 
 
 
 
 
 
 
Non-standard Abbreviations and Acronyms 
 
BMP    bone morphogenetic protein 
BMPR   bone morphogenetic protein receptor  
BUN   blood urea nitrogen  
CKD   chronic kidney disease 
CS   chondroitin sulfate 
CSPG  chondroitin sulfate proteoglycan  
GAG   glycosaminoglycan 
GFR   glomerulus filtration rate 
ECM   extracellular matrix 
EXTL2 KO exostosin-like glycosyltransferase 2 knockout  
HPLC   high performance liquid chromatography 
HS   heparan sulfate 
MGP   matrix gla protein 
OPN   osteopontin  
Runx2  runt-related transcription factor 2 
VSMCs  vascular smooth muscle cells 
GlcNAc   N-acetylglucosamine 
 
 
 
 
 
 
 Introduction 
 
 Vascular calcification accelerates the progression of cardiovascular disorders in patients 
with chronic kidney disease (CKD).1 Calcification of blood vessels reduces their elasticity 
and promotes arterial stiffness, increases blood and pulse pressure and the risk of heart 
failure.2-4 Current therapeutic strategies for vascular calcification focus on correction of the 
disordered bone and mineral metabolism that accompanies CKD.5 Vitamin D receptor 
agonists and calcimimetics provide survival benefits and delay the progression of vascular 
calcification, respectively.6, 7 In addition, controlling the serum phosphate level using 
phosphate binders, sevelamer, and lanthanum offers the advantage of a low incidence of 
vascular calcification in CKD patients.8, 9 However, despite the improvement of 
cardiovascular function and structure by sevelamer hydrochloride, other studies failed to 
demonstrated a significant difference in the progression of vascular calcification between 
calcium acetate and sevelamer hydrochloride. Furthermore, inconsistent results of sevelamer 
effects on mortality in HD patients have been shown in some studies.10 Even though several 
potential therapies that directly ameliorate vascular calcification have presented beneficial 
effects in animal and human studies11, the effects of these therapies appear to be insufficient; 
therefore, no effective regiment is currently available for the treatment of vascular 
calcification.12 A deeper understanding of vascular calcification mechanisms is strongly 
necessary to provide novel strategies for the treatment of vascular calcification in CKD 
patients.  
 Vascular smooth muscle cells (VSMCs) represent the predominant cell type in the 
arterial walls and actively transdifferentiate into an osteoblastic/chondrocytic-like phenotype 
during the development of vascular calcification.13, 14 Similar to bone cells, transdifferentiated 
VSMCs express osteoblastic differentiation factors such as runt-related transcription factor 2 
(runx2), osteopontin (OPN), and matrix gla protein (MGP) which regulate the vascular 
calcification process.15-17 Extracellular matrix (ECM) components that provide a unique 
environment for hydroxyapatite mineralization in bone formation18, 19 are considered 
important factors in the regulation of the progression of vascular calcification. Some ECM 
molecules such as fibronectin and collagen I induce the in vitro calcification of vascular cells, 
whereas other molecules such as collagen IV inhibit this process.20 Accumulation of 
proteoglycans, another ECM component, in intimal and medial calcification is associated 
with atherosclerotic plaques as well as calcified nodules in the aortic valve, suggesting that 
proteoglycans are involved in the development of vascular calcification. 21-23  
 Heparan sulfate (HS) and chondroitin sulfate (CS) are glycosaminoglycan (GAG) 
chains expressed at the cell surface and in the extracellular matrix, and modulate various 
aspects of physiologic and pathologic conditions.24-26 These molecules are composed of 
repeated disaccharide units of N-acetylated hexosamine and hexuronic acid that covalently 
bind to the core protein of proteoglycans through a tetrasaccharide linkage. Sulfation of N-
acetylated hexosamine and hexuronic acid provides negative charges that enable the binding 
of ligands.25-28 The ubiquitous expression of these molecules in various tissues, particularly 
blood vessels, suggests a contribution to vascular development as well as the progression of 
vascular diseases.29-31 Given their roles in osteogenesis32-36, GAGs may contribute to the 
osteoblastic differentiation of VSMCs during vascular calcification. However, few studies 
have addressed the role of GAG modification in the progression of vascular calcification in 
CKD.  
 To evaluate the role of GAGs in aortic calcification, we used exostosin-like 
glycosyltransferase 2 deficient (EXTL2 KO) mice, which overexpress GAGs.37 The mice 
were subjected to 5/6 subtotal nephrectomy and administered a high-phosphate diet to induce 
CKD. In this study, we also demonstrated the involvement of GAGs in vascular calcification 
 through ex vivo and in vitro studies using aortic rings and VSMCs of EXTL2 KO mice, 
respectively. Our study provides evidence that increased GAG expression in murine aortas in 
CKD augments aortic calcification. In addition, deletion of GAG in VSMCs effectively 
attenuates in vitro calcification.  
 
Material and methods 
 
1. Animal Studies 
The Animal Research and Ethics Committee of Kobe Pharmaceutical University, Kobe, 
Japan approved all our animal procedures. In this study, we used EXTL2 KO mice (n=23) 
and their wild-type (WT) littermates (n=25) that were previously generated.37 Both strains 
were maintained on a C57BL/6 genetic background. Male mice aged 8-10 weeks were 
anesthetized with sodium pentobarbital and subjected to 5/6 sub total nephrectomy with 2 
steps surgery procedure, as described previously (EXTL2 KO n=15; EXTL2 WT mice 
n=16).38 Sham operated mice were used as control (EXTL2 KO mice n=8; EXTL2 WT mice 
n=9). After completion of the 5/6 sub total nephrectomy, mice received high-phosphate diet 
containing 1.5% phosphate (termed as CKD groups). Sham-operated groups received normal-
phosphate diet containing 0.5% phosphate (termed as control groups) (MF high phosphate 
diet and MF normal diet (Oriental Yeast Co. Ltd., Osaka, Japan)). Mice were sacrificed after 
8 weeks of diet administration. 
 
2. Systemic Parameters 
 Mouse body weight was measured before and at the end of experiment. Systemic blood 
pressure was determined by tail-cuff methods system (Softron, Tokyo, Japan) following the 
acclimatization procedure in conscious mice and repeating 10 times measurement for each 
mouse. Using metabolic cages, one day prior to sacrifice date, urine was collected. In the end 
of experiment, blood was taken by cardiac puncture. Blood urea nitrogen (BUN), and serum 
phosphate were analyzed by urease-GLDH method and enzymatic fluorimetric assay for 
glucose-6-phosphate, respectively. Serum and urine creatinine were measured by enzymatic 
assay (Nescoat VLII CRE kit, Alfresa Pharma Corporation, Osaka, Japan). Glomerulus 
Filtration Rate (GFR) was estimated by measuring the mouse creatinine clearance. Aortic 
tissue was prepared for calcium measurement, RNA, and histological examinations. Thoracic 
aorta was used for histology samples and abdominal aorta was used for calcium and RNA 
measurement.   
 
3. In vitro and ex vivo calcification 
Mouse VSMCs were isolated from aorta of control animals (3 mice for each genotype), as 
previously described.39 Briefly, aorta was isolated and dissected from the fibrous and lipid 
tissue in the surrounding area.  In the sterile culture medium, aorta was cut in to small pieces 
approximately 1-2 mm on side, and then incubated with type 2 collagenase at 37 ˚C for 6 
hours. VSMCs were detached from the tissue by flicking gently, transferred and incubated in 
48 well culture dishes, then leaved undisturbed for 5 days. Cells with passage number 3-10 
were used for experiment. Cells were culture with DMEM high glucose (WAKO, Osaka, 
Japan), containing 15% FBS (Biowest, Nuaillé, France), 1% (v/v) 
penicillin/streptomycin/amphotericin B (Wako, Osaka, Japan), 1 mM sodium pyruvate 
(Gibco Invitrogen Corporation, New York, USA) until 90-100% confluence then treated with 
high phosphate medium (phosphate inorganic (Pi) = 3 mM) or normal medium (Pi = 0.9 mM) 
as the normal control for 6 days. Medium was changed every other day. Heparitinase (EC 
4.2.2.8, 10 mIU/ml) and chondroitinase ABC from Proteus vulgaris (EC 4.2.2.4, 20 mIU/ml) 
were added to remove HS and CS from the cell surface of VSMCs.  Three separated wells 
 were used for each group of treatment. For ex vivo calcification, the dissected thoracic aorta 
was cut in to small rings with a length of approximately 4-5 mm and cultured with a normal 
or high phosphate medium for 6 days. Four aortas from four different control mice were used 
for each group of treatment.  
 
4. Calcium quantification 
Aortic and cellular calcium were extracted in the 200 µl of HCl 0.6 M at 4˚C for 24 hours, 
and transferred into new tube for calcium quantification. Aortic, cellular, and serum calcium 
level were determined by o-Cresophtalein Complexone (Sigma-Aldrich, Missouri, USA) and 
commercial detection reagents, according to manufacture’s protocol. Protein was extracted 
from aortic samples and cells by incubation with 10% NaOH and 1% SDS, and then 
subjected to protein concentration measurement.  The aortic calcium content (µg) was 
standardized using aortic dry weight (mg). In vitro and ex vivo calcium amount (µg) was 
standardized based on the protein content (mg). 
 
5. Quantitative real-time PCR 
Messenger RNA was extracted by TRIzole reagent (Gibco Invitrogen Corporation, New 
York, USA). The extracted RNA was digested with RQ1 RNase-free DNase and stop solution 
(Promega, Wisconsin, USA) for 30 minute at 37˚C and 10 min at 65˚C, respectively. Reverse 
transcriptase PCR was performed by using Murine-Moloney Leukemia Virus Reverse 
Transcriptase (Gibco Invitrogen Corporation, New York, USA) with random primers (Takara 
bio Inc., Shiga, Japan). Quantitative real-time PCR was performed using Fast Start DNA 
Master plus SYBR Green I and a LightCycler 1.5 (Roche Applied Science, Indianapolis, 
USA) according to the manufacturer’s procedures. The primers are: 
- mouse matrix gla protein (MGP):   
o forward primer    : ccg aga cac cat gaa gag c 
o reverse primer   : gat tcg tag cac agg gttg  
- mouse osteopontin (OPN) : 
o forward primer      : ccc ggt gaa agt gac tga t 
o reverse primer  : ttc ttc aga gga cac agc att c 
- mouse bone morphogenetic protein 2 (BMP2) : 
o forward primer      : atg taa tca gaa gaa ata tcg ggt 
o reverse primer  : gga ctt gaa ctt gtg aac ttt aac 
- mouse BMP receptor type Ia (BMPRIa) : 
o forward primer      : cca tta tag aag aag atg atc agg g  
o reverse primer  : ctg caa ata ctg gtt gca c 
- mouse BMP receptor type II (BMPRII) : 
o forward primer      : agg cag cca aca tag tg  
o reverse primer  : agg cag cca aca tag tg  
- mouse  glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
o forward primer      : cat ctg agg gcc cac tg 
o reverse primer  : gag gcc atg tag gcc atg a 
 
6. Immunohistochemistry and histology 
 Aortic tissue was fixed in the 4 % paraformaldehyde in PBS (phosphate-buffered saline)   
(v/v) at 4 ˚C for overnight. The fixated aorta was subjected to paraffin or frozen block 
preparation. Four µm slides were used for hematoxyllin-eosin staining and 
immunohistochemistry. After performing antigen retrieval step using citrate buffer, the 
samples were permeabilized using 0.05% triton X-100 in PBS (v/v) and blocked in the 5% 
BSA (bovine serum albumin) in PBS (v/v). The primary antibodies are anti heparan sulfate 
 antibody, HepSS-1, anti chondroitin sulfate antibody, 3B3, 1:100 (Seikagaku Biobusiness 
Corporation, Tokyo, Japan), anti phosphorylated (p)-smad1/5/8 antibody 1:100, anti smooth 
muscle (SM)-22α antibody 1:100 (Cell Signaling Technologies, Massachusetts, USA), anti α-
Smooth Muscle Actin (SMA)-FITC antibody 1:100 (Sigma Aldrich Corporation, Missouri, 
USA), anti Runx2 antibody, 1:100 (Santa Cruz Biotechnology Inc., Texas, USA). After 
adequate washing step, the samples sections were incubated with appropriate secondary 
antibodies. Images were captured with an LSM 710 laser-scanning confocal microscope using 
a 20x objective. Overt matrix mineralization and calcium deposition in the mouse aorta and 
VSMCs were detected by Von Kossa staining and alizarin red, respectively.  
 
7. GAG fluorescent labeling and immunocytochemistry. 
Mouse VSMCs were fixed in 4% PFA in PBS (v/v). Fixated cells were permeabilized in 
0.05% Triton X-100 in PBS (v/v) prior to blocking with 5% BSA in PBS (v/v). HepSS-1 and 
CS56 primary antibodies (Sigma Aldrich Corporation, Missouri, USA) were used for labeling 
the heparan sulfate and chondroitin sulfate, respectively. To observe apoptosis process, anti 
Caspase 3 antibody (Santa Cruz Biotechnology Inc., Texas, USA) was used. After incubation 
with the appropriate secondary antibodies, images were captured using an LSM 710 laser-
scanning confocal microscope with a 10x objective. 
 
8. Proliferation and migration assays 
To examine the proliferation activity of VSMCs, the cell proliferation reagent WST-1 was 
used according to manufacture’s protocol. Briefly, VSMCs (4 x 103 cells / well) were culture 
to 50% confluence. The cells were treated with medium containing 15 % fetal bovine serum. 
The chondroitinase ABC and heparitinase were added to the well of enzymes treated group. 
Cells with free serum medium were used as a control.  After 24 hours incubation, 10 µl WST-
1 reagent were added to each well and the cells were re-incubated for another 2 hours. The 
color intensity was read at 450 nm (reference wavelength 655nm). To measure migration 
activity, we used scratch wound assay as described previously.40 VSMCs were seeded into 6 
well dishes. Confluent monolayers were scraped through the middle of the dish by using a 
modified 100µl tip. After wounding, monolayers were immediately washed with DMEM and 
incubated with 15% FBS. Heparitinase and chondroitinase ABC were added in enzymes 
treated group.  After 48 hours, wound closure area from the wound edge was quantified. 
 
9. BMP2 accumulation assay in aortic tissue 
Recombinant human BMP2 (rhBMP2) (R&D systems, Minnesota, USA) (1 µg/mL) was pre-
incubated with goat anti-polyclonal BMP2 (Santa Cruz Biotechnology Inc., Texas, USA) (2 
µg/mL) at 37°C for 30 minutes. Fixed aortic tissue was incubated with the ligand-antibody 
complex at 4°C for 30 min. Following incubation, the aortic tissues were washed with PBS 
and blocked using 5% BSA at room temperature for 30 min. The aortic samples were 
incubated in donkey anti-goat Alexa Fluor 488-conjugated secondary antibody. Fluorescence 
was visualized using an LSM 710 laser-scanning confocal microscope with a 20× objective. 
 
10. Disaccharide composition analysis in aortic tissue 
The aorta was harvested from 8-wk-old male mice (3 mice for each genotype), homogenized 
in cold acetone, and evaporated overnight. The resulting dry powder was digested by actinase 
E at 55°C for 24 h. The digested sample was resuspended in 5% trichloroacetic acid and 
centrifuged, and the supernatant was extracted using diethyl ether. The aqueous phase was 
neutralized and precipitated using 80% ethanol. The precipitate was dissolved in pyridine 
acetate buffer and subjected to filtration on a PD-10 column (GE Healthcare, 
Buckinghamshire, UK). The flow-through products were evaporated and the dried samples 
 were digested using a mixture of heparitinase (EC 4.2.2.8, 1 mIU) and heparinase (EC 
4.2.2.7, 1 mIU) from Flavobacterium heparinum or chondroitinase ABC from Proteus 
vulgaris (EC 4.2.2.4, 10 mIU) at 37°C for 4 h. The digested GAGs were derivatized using the 
fluorophore 2-aminobenzamide and then analyzed by high-performance liquid 
chromatography (HPLC) - SLC-10A system (Shimadzu, Kyoto, Japan) on a PA-03 column 
(YMC, Kyoto, Japan) as reported previously.41 
 
11. Statistical analysis  
Results are presented as the mean ± SEM. The data distribution was tested using 
Kolmogorov-Smirnov test. Normally distributed variables were analysed using ANOVA 
followed with Unpaired Student’s t-test. Variables not normally distributed were analyzed 
using non-parametric analysis with Kruskal Wallis followed by Mann Whitney U test. All 
analyses were performed using GraphPad Prism software (GraphPad, California, USA). 
Differences were considered significant when p < 0.05. 
 
Results 
 
Augmented GAG chains (HS and CS) in aortas of EXTL2 KO mice  
The disaccharide content of GAG chains (HS and CS) in the aortas of EXTL2 KO mice was 
higher than that in the aortas of WT mice (Table 1 and 2). We also examined disaccharides 
composition on those mice and found that 6-sulfation pattern composition of CS in EXTL2 
KO mice is higher compared with in EXTL2 WT mice. 
 
Equal development of CKD in EXTL2 KO and WT mice following 5/6 subtotal 
nephrectomy and high-phosphate diet administration 
To determine the presence of CKD, BUN and GFR were measured in EXTL2 KO and WT 
mice. In both CKD groups, the kidney function was markedly reduced, as demonstrated by 
higher BUN and lower GFR (Figure 1A and 1B). No significant difference between the 2 
genotypes was observed under normal conditions. As expected, the high-phosphate diet in the 
CKD group induced high serum phosphate levels, with no effect on serum calcium levels; 
thus, the serum Ca x P product was increased in both genotypes (Figure 1C-E). The mouse 
body weight decreased in all CKD groups, and a lower body weight was detected in EXTL2 
KO mice (Figure 2A). SBP levels were elevated in EXTL2 KO mice suffering from CKD 
(Figure 2B).  
 
Increased aortic calcification in aortas of EXTL2 KO mice with CKD 
Reduced renal function and high phosphate levels contribute to the development of aortic 
calcification. We determined the aortic calcification by qualitative and quantitative method, 
which are Von Kossa staining and aortic calcium content measurement, respectively. We 
used Von Kossa staining to show overt calcification. We found that Von Kossa staining was 
positive only in 5 out of 15 of EXTL2 KO mice in CKD condition, which mean 30% of the 
mice in this group showed overt calcification (Figure 3A-H). Calcification was mainly visible 
in the media layer of aorta, within and surrounding elastic fibers; this layer predominantly 
consists of vascular smooth muscle cells. All other experimental groups did not show overt 
signs of calcification. Furthermore, to measure the extent of aortic calcification; we measured 
calcium content in aorta. Even tough, not all EXTL2 KO mice under CKD showed overt 
calcification; the average of the calcium content in this group is the highest among all groups 
(Figure 3M). To confirm that HS and CS chains are important for aortic calcification, isolated 
aortic rings from control mice of both genotypes were cultured in normal or high-phosphate 
medium. As shown in Figure 3N, although the high-phosphate medium elevated the calcium 
 deposition in both genotypes, the aorta of EXTL2 KO mice demonstrated significantly higher 
calcium deposition than that of WT mice.  
 
Alterations in bone matrix components and vascular smooth muscle cell markers in the 
calcified aorta of EXTL2 KO mice.  
Immunostaining revealed a high expression of the osteoblastic differentiation markers Runx2 
(Figure 4E–M) and type Ia collagen (Figure 5E-M) in the calcified aorta of EXTL2 KO mice, 
but little or no expression in the other groups. Concomitant with the calcium deposition in the 
aorta, the mRNA level of MGP increased in the EXTL2 KO mice with calcified aortas 
compared to that in WT mice with CKD, and the other control groups (Figure 6A). Similarly, 
the OPN mRNA level was up-regulated in the calcified aorta of EXTL2 KO mice (Figure 
6B). In addition, calcified aorta of EXTL2 KO mice demonstrated a loss of vascular smooth 
muscle cell markers such as SM22- α and α-SMA (Figure 7). 
 
CKD increases HS and CS levels in calcified and non-calcified aortas  
The accumulation of extracellular matrix components in calcified lesions is considered to 
stimulate subsequent vascular calcification. In the present study, HS and CS levels were 
much higher in the calcified aortas of CKD-induced EXTL2 KO mice than in the aortas of 
control EXTL2 KO mice, which already showed an up-regulation of HS and CS in their 
aortas. HS and CS levels were also increased in the non-calcified aortas of CKD-induced WT 
mice (Figure 8). 
 
 
Attenuation of HS or CS expression decreases calcium deposition in VSMCs cultured in 
high-phosphate conditions 
Heparitinase and chondroitinase treatment effectively reduced heparan sulfate and 
chondroitin sulfate expression in cell surface of VSMCs, respectively (Figure 9). These 
treatments have no significant effects on proliferation, migration, and apoptosis activity in 
treated VSMCs (Figure 10). Under high-phosphate treatment, alizarin red staining and 
calcium quantification revealed matrix mineralization in mouse VSMCs (Figure 11). In 
support of the in vivo results, EXTL2 KO VSMCs that overexpressed HS and CS 
demonstrated higher calcium deposition (1/3-fold increase) under the high-phosphate 
condition than those from WT mice. To investigate which GAG contributed to vascular 
calcification, removal of HS or CS by enzymatic digestion was performed in vitro in high 
phosphate-containing mouse VSMCs. Heparitinase treatment effectively decreased the 
amount of alizarin red staining and the calcium level in high-phosphate-induced mouse 
VSMCs. Furthermore, treatment with chondroitinase also markedly reduced matrix 
mineralization and calcium deposition in high phosphate-containing EXTL2 KO and WT 
mouse VSMCs. 
 
Up-regulation of BMP2 signaling in the calcified aorta  
Many studies have shown that BMP2 signaling positively contributes to osteoblastic 
differentiation of VSMCs during vascular calcification. In the present study, we observed that 
BMP2 mRNA was increased in both CKD groups. No difference was observed in the 
expression of BMPR Ia and BMPR II. P-Smad1/5/8 expression downstream of BMP 
signaling was only detected clearly in the calcified aortas of EXTL2 KO mice (Figure 12). In 
addition, extracellular BMP2 accumulated to a greater extent in the calcified aorta than in the 
WT aorta (Figure 13).  
 
 
 Discussion   
 
In this study, we demonstrate that the overexpression of HS and CS contributes to vascular 
calcification in CKD in vivo. We also confirmed the involvement of HS and CS in vascular 
calcification by ex vivo and in vitro studies. Under high phosphate condition, the calcium 
deposition was increased in aortic tissue samples and aortic VSMCs derived from EXTL2 
KO mice compared to those from WT mice. Furthermore, deletion of HS or CS in mouse 
VSMCs decreased the amount of calcium deposition. These findings suggest that HS and CS 
enhanced the vascular calcification progression in high phosphate condition.  
 To evaluate the involvement of HS and CS in vascular calcification, we used EXTL2 
KO mice, which show elevated HS and CS expression. EXTL2 is an enzyme involved in HS 
and CS biosynthesis; in particular, it has transferase activity, and mediates the transfer of the 
first N-acetylglucosamine (GlcNAc) via an α1, 4 linkage to a phosphorylated tetrasaccharide 
core region, which results in the termination of HS and CS.25, 37, 42 Deletion of EXTL2 in 
mice disturbs this process and permits the accumulation of HS and CS in vivo. EXTL2 KO 
mice show an increased HS and CS expression in the liver, brain, and embryonic 
fibroblasts.37 In the present study, we also observed high HS and CS expression in the aorta 
of these mice. HS and CS were clearly expressed in the aorta, particularly in the sub-
endothelial and medial layers. It is likely that the lack of EXTL2 in mice did not affect their 
growth process, as they grew normally and had normal blood pressure under physiologic 
conditions. In addition, there is no study reported about the role of EXTL2 and other EXT’s 
families beyond regulation of GAG biosynthesis. Therefore, we considered that the excess 
GAG expression in the EXTL2 KO mouse might contribute during pathologic condition 
particularly in the vascular calcification development. Supporting our study, current report by 
Nadanaka et al. showed the important role of EXTL2 mediated GAG synthesis in 
regenerating process during liver injury.43 Regarding our hypothesis that GAG 
overproduction might have deleterious effects during vascular calcification, we used mice of 
the C7BL/6J strain that are relatively resistant to vascular calcification44, which favor us to 
evaluate the role of HS and CS in enhancing vascular calcification.  
 The severity of CKD has important role in the development of vascular calcification. 
Therefore, we examined the kidney function in all comparable group mice. However, we 
observed that kidney functions did not differ between EXTL2 KO and WT mice, under either 
normal conditions or following CKD induction. Considering the importance of phosphate in 
the development of vascular calcification, we also examined the serum phosphate 
concentration in all treatment groups. We found that the phosphate concentration was not 
affected by genotypic differences. Systolic blood pressure was initially similar among all the 
treatment groups. In our study, EXTL2 KO mice did not develop aortic calcification 
spontaneously. Interestingly, after 2 months of CKD with high phosphate condition, we found 
that EXTL2 KO mice clearly showed more vascular calcification than WT mice and observed 
that those mice developed higher systolic blood pressure than WT mice. We assume that 
vascular calcification, which is accompanied by increased stiffness and decreased compliance 
of arteries45, 46, increased systolic blood pressure. From these results, we suggest that 
overproduction of GAG in EXTL2 KO mice enhanced the aortic calcification under CKD 
with high phosphate condition. 
 To support the in vivo finding that demonstrate the GAG role in vascular calcification, 
we also did ex vivo study using aortic ring and in vitro study using aortic VSCMs which are 
isolated from control mice of both EXTL2 KO and WT mice. Our ex vivo study showed that 
aortic ring tissue from EXTL2 KO mice has higher calcium deposition than that from WT 
mice in the presence of high-phosphate medium. In vitro study showed that VSMCs of 
EXTL2 KO mice under high phosphate medium have higher calcium deposition than those of 
 other groups. Futhermore, we also showed that deletion HS and CS using heparitinase and 
chondroitinase, respectively result in lowering the calcium deposition under high phosphate 
conditions. These results confirmed that over expressed GAG might contribute in aortic 
calcification under high phosphate conditions.  
 Previous studies suggested that proteoglycan contributes to the progression of vascular 
calcification. Decorin, a chondroitin sulfate proteoglycan (CSPG), was found at sites of 
calcification within the aortic valve23 and atherosclerotic plaque of human coronary arteries.21 
Increased decorin expression promotes in vitro calcification of VSMCs.21 In addition, other 
CSPGs, biglycan, and versican were expressed in calcified nodules and areas surrounding 
calcified lesions in the aortic valve, which suggests that biglycan and versican actively induce 
and modulate soft tissue mineralization, respectively.23 However, these studies provide no 
evidence for the contribution of HS and CS to vascular calcification. Our study suggests that 
accumulation of HS and CS in the mice aorta contributes to matrix mineralization in the 
aorta. The negative charges of sulfate residue in HS and CS create ligand-binding sites and 
modulate their activity. The most well-known growth factor ligand related to osteoblastic 
differentiation is BMP2. By acting as a co-receptor for BMP2, HS accelerates the formation 
of a complex between BMP2 and BMP receptors, and contributes to enhance BMP2 
signaling.27 HS modulates the distribution of BMP2 on the cell surface, prolongs the half-life 
of BMP2, and reduces the interaction of BMP2 with its antagonist.34 In a human study, 
Koleganova et al. observed that BMP2 expression was higher in the aorta of CKD patients 
than in controls, but no difference was found between calcified and non-calcified aortas.47 
Consistent with this study, we observed higher level of BMP2 in CKD mice than control 
mice. However, we did not observe any difference in BMP2 and BMPR receptor expression 
in both CKD groups. Interestingly, p-smad1/5/8 activation was detected higher in the 
calcified aortas of EXTL2 KO mice than aorta of other groups. These results suggested that 
overproduction of HS might mediate the BMP2 binding with BMP receptors and activate the 
signal transduction. To visualize BMP2 distribution in aortic tissue, we performed BMP2 
accumulation assays and found that BMP2 was more abundantly accumulated in calcified 
aortas than in tissues from other groups. It is likely that high HS and CS levels in CKD 
contribute to the attachment of BMP2 to BMP receptors and the activation of downstream 
signaling. Activation of BMP2 signaling has been further shown to affect the phenotypic 
transition of VSMCs48. Similarly; we detected high expression of Runx2, an osteoblastic 
differentiation factor, and low expression of the VSMC markers SM22-α and α-SMA in the 
calcified aorta. These findings suggest that under high phosphate condition, high HS and CS 
levels in the aortas of EXTL2 KO mice accelerate vascular calcification by enhancing BMP2 
signaling through p-smad1/5/8, which further induces phenotypic transition of VSMCs.  
 In addition, previous studies showed that sulfation pattern of GAG contributes in the 
various mechanisms.49, 50 In our study, we also measured the disaccharides composition and 
found that the 6-sulfation pattern but not 4-sulfation of CS in EXTL2 KO mice is higher 
compare to those on EXTL2 WT mice but. During osteoblastic differentiation, CS-C, which 
consists of 6-O-sulfate at its N-acetylated hexosamine and hexuronic acid residues, activates 
p-smad1/5/8 expression. However, CS-E, which is enriched with 4-O-sulfate and 6-O-sulfate 
at its N-acetylated hexosamine and hexuronic acid residues, activates p-smad1/5/8 expression 
with higher level than CS-C.36 Despite the modest role of 6-sulfation during osteoblast 
differentiation, the change of disaccharides composition in EXTL2 KO mice may also 
contribute in the vascular calcification development. Nevertheless, further study is needed to 
elucidate the importance of 6-sulfation pattern during vascular calcification development.  
 In the in vitro study, we demonstrated that under high phosphate condition, 
overexpression of GAG enhanced calcium deposition in mouse VSMCs and deleting the cell 
surface and extracellular matrix HS or CS from mouse VSMCs effectively abrogated the 
 calcification.  
 In conclusion, we are the first to demonstrate the importance of HS and CS in CKD-
induced vascular calcification. Up-regulation of HS and CS in aortic tissue clearly accelerates 
the progression of vascular calcification in animals with CKD. Attenuation of HS or CS 
effectively reduces the calcium deposition in VSMCs under high phosphate condition. 
Considering the complexity of vascular calcification mechanisms, a balance between vascular 
calcification inducers and inhibitors is necessary. These results suggest that controlling HS 
and CS expression may help in preventing or inhibiting the progression of vascular 
calcification in CKD. 
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 TABLE LEGENDS 
 
TABLE 1 
Aorta of EXTL2 KO mice contains higher HS amounts than those of WT mice. 
Disaccharide composition of HS from aorta of 8 weeks old male mice. Data are shown as 
pmol of disaccharide per mg of acetone powder of aorta, the mean ± S.E.M, and percentage 
from total amount of three independent experiments. 
* p < 0.05 vs WT mice by Unpaired Student’s t-test. 
 
TABLE 2 
Aorta of EXTL2 KO mice contains higher CS amounts than those of WT mice. 
Disaccharide composition of CS from aorta of 8 weeks old male mice. Data are shown as 
pmol of disaccharide per mg of acetone powder of aorta, the mean ± S.E.M, and percentage 
from total amount of three independent experiments. 
* p < 0.05 vs WT mice by Unpaired Student’s t-test. 
 
FIGURE LEGENDS  
FIGURE 1 
Development of CKD that represented by serum chemistry was independent from 
genotype of all groups. (A) All mice under CKD groups have higher blood urea nitrogen 
(BUN), reaching two folded differences than control groups. (B) In addition, both EXTL2 
KO and WT mice in CKD groups have lower glomerular filtration rate (GFR) approximately 
50% less than in the control groups. (C) Mice with CKD condition show significantly higher 
serum phosphate than control groups. (D) However, serum calcium concentration was 
determined in same level in all-comparable groups. (E) The product of serum calcium x 
phosphate was higher in CKD groups than control groups. Data are shown as mean ± S.E.M 
(n = 3-6) * p < 0.05, ** p < 0.01; BUN, serum phosphate, and serum calcium by Unpaired 
Student’s t-test; GFR and serum Ca x P product by Mann Whitney U test. 
 
FIGURE 2 
Chronic kidney disease influenced body weight and blood pressure after 2 months 
treatment. (A) After 2 months treatment, marked weight loss was found in all CKD groups. 
Besides, EXTL2 KO mice have lower body weight than WT mice. (B) CKD induced EXTL2 
KO mice have remarkably higher systolic blood pressure than its control and WT mice. Data 
are shown as mean ± S.E.M (n = 7-9), * p < 0.05, ** p < 0.01, *** p < 0.005 by Unpaired 
Student’s t-test .  
 
FIGURE 3 
Deleting EXTL2 gene aggravated aortic calcification under CKD. (A-H) Calcium 
deposition (black color) visualized by Von Kossa staining was predominantly in the aortic 
media. (I-L) Aortic structure was shown by hematoxylin and eosin staining. (M) 
Quantification of calcium content in the mice aorta has shown that EXTL2 KO mice under 
CKD developed more calcium deposition than WT mice (Control group, n = 5-6; CKD group, 
n = 15-16). Data are shown as mean ± S.E.M, * p < 0.05, ** p < 0.01 by Mann Whitney U 
test. (N) Calcium deposition quantification in aortic culture of EXTL2 KO and WT mice after 
6 days phosphate treatment (n = 5 separated mice). Data are shown as mean ± S.E.M, *** p < 
0.005 by Unpaired Student’s t-test . 
 
 
 
 FIGURE 4 
Enhancement of Runx2 in EXTL2 KO mice aorta. (A-D) Serial section of each group was 
detected by Von Kossa staining. (E-L) Runx2, which is related with osteoblastic 
differentiation, was enhanced in the calcified aorta of EXTL2 KO mice. (M) Quantification 
result of Runx2 signal per aortic area. Data are shown as mean ± S.E.M (n = 6), * p < 0.05 by 
Mann Whitney U test. 
 
FIGURE 5 
Augmentation of collagen Ia in calcified aorta of EXTL2 KO mice. (A-D) Serial section 
of each group was detected by Von Kossa staining. (E-L) Collagen Ia was up-regulated in 
calcified aorta of EXTL2 KO mice. (M) Quantification result of collagen Ia signal in aortic 
area. Data are shown as mean ± S.E.M (n = 6), *** p < 0.005 by Unpaired Student’s t-test . 
 
FIGURE 6 
Enhancement of bone matrix components in EXTL2 KO mice aorta. (A,B) Quantitative 
real time PCR results show an up regulation of MGP and OPN in calcified aorta.  Data are 
shown as mean ± S.E.M (n = 4-6). * p < 0.05 by Mann Whitney U test.  
 
FIGURE 7 
Vascular smooth muscle cells loss in calcified aorta of EXTL2 KO mice. . (A-D) Serial 
section of each group was detected by Von Kossa staining. (E-L) α-SMA and (M-T) SM22-α 
as contractile phenotype markers of VSMC were highly expressed in both control groups and 
CKD group of WT mice. However, their expression was attenuated in calcified aorta of 
EXTL2 KO mice under CKD condition. Quantification result of α-SMA (U) and SM22-α (V) 
signal in aortic area. Data are shown as mean ± S.E.M (n = 6), * p < 0.05, ** p < 0.01, *** p 
< 0.005 by Unpaired Student’s t-test . 
 
FIGURE 8 
Heparan sulfate and chondroitin sulfate signals were increased in CKD treated group. 
(A-D) Serial section of each group was detected by Von Kossa staining. HS and CS 
expression in mice aorta were detected by HepSS-1 (E-L) and 3B3 (Q-X) antibody, 
respectively. Their expression were up-regulated under CKD. HepSS-1 and 3B3 signal was 
quantified and shown as percentage per aortic area (Y and Z, respectively). Data are shown as 
mean ± S.E.M (n = 6). * p < 0.05, ** p < 0.01, *** p < 0.005 by Unpaired Student’s t-test . 
  
FIGURE 9 
Heparan sulfate and chondroitin sulfate expression was reduced under enzymes 
treatment. (A, B, E, F) Heparan sulfate expression and (C, D, G, H) chondroitin sulfate 
expression was reduced after heparitinase and chondroitinase treatment, respectively. HepSS-
1 and CS56 signal were quantified and shown as percentage per measured area (I and J, 
respectively). Data are shown as mean ± S.E.M (n = 6). *** p < 0.005 by Unpaired Student’s 
t-test . 
 
FIGURE 10 
Proliferation, migration, and apoptosis activity are not affected by enzymes treatment. 
(A) Proliferation and (B) Migration activity of both genotypes VSMCs were not significantly 
different and not affected by heparitinase or chondroitinase treatment. (C) Caspase 3 
expression was in the similar level in all treated groups. Data are shown as mean ± S.E.M (n 
= 3) by Mann Whitney U test. 
 
 FIGURE 11 
Removal of HS and CS cell surface structure ameliorated calcium deposition of high 
phosphate treated VSMCs. (A, B, E, F) Alizarin red positive area was markedly up 
regulated in phosphate treated cells and extensive positive area was found in EXTL2 KO 
mouse VSMCs. (C, G) Removal of HS by using heparitinase 10 mIU/ml effectively 
attenuated calcium deposition under high phosphate condition. (D, H) Chondroitin sulfate 
digestion by chondroitinase 20 mIU/ml treatment also decreased the amount of calcium 
deposition in high phosphate treatment. (I) Calcium deposition was quantified by o-
Cresophtalein Complexone method in all comparable groups. Data are presented as mean ± 
S.E.M (n = 3). * p < 0.05, δ < 0.001, ƒ p < 0.0005, # p < 0.0001 by Unpaired Student’s t-test . 
 
FIGURE 12 
Activated BMP signaling in calcified aorta of EXTL2 KO mice. Phosphorylated-smad 
1/5/8 was enhanced in calcified aorta of EXTL2 KO mice (H, L) but not in other groups (E-
G, I-K). P-smad 1. 5, 8 signal was quantified and shown as percentage per aortic area (M) 
The mRNA expression of BMP2 ligands determined by qRT-PCR showed increased in both 
CKD groups. However, no significant different of BMP2 expression in CKD groups was 
found (N). We observed no differences in both BMP receptor type Ia (BMPRIa) and BMP 
receptor type II (BMPRII) (O and P). Data are presented as mean ± S.E.M (n = 4-5). *p < 
0.05, **p < 0.001, n.s. = not siginificant by Mann Whitney U test. 
 
FIGURE 13. BMP2 accumulation in calcified aorta. Exogenous rhBMP2 was more 
abundantly trapped on calcified aorta  (H, L) than WT CKD and both control groups (E - G, I 
- K).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE 1 
Disaccharide composition of HS from aorta of EXTL2 KO or WT mice 
Composition  
Aorta {pmol/mg (mol %)} 
EXTL2 KO WT 
∆ DiHS-0S 464.6 ± 70.7 (38.4) 239.8 ± 70.7 (38.4) 
∆ DiHS-6S 35.3 ± 13.7 (3.1) 28.5 ± 13.4 (4.6) 
∆ DiHS-NS 535.2 ± 67.0 (46.4) 266.5 ± 43.1 (42.7) 
∆ DiHS-diS1 21.9 ± 7.2 (1.9) 12.7 ± 4.6 (2.0) 
∆ DiHS-diS2 82.2 ± 6.6 (7.1) 69.2 ± 16.9 (11.1) 
∆ DiHS-TriS 14.5 ± 3.5 (1.3) 7.5 ± 3.8 (1.2) 
Total 1153.8 ± 209.2 (100)* 624.4 ± 139.6 (100) 
Abbreviations:  
∆DiHS-0S, ∆HexUA α1-4GlcNAc; ∆DiHS-6S, ∆HexUA α1-4GlcNAc(6S); ∆DiHS-NS, ∆HexUA α1-4GlcNS; ∆DiHS-diS1, 
∆HexUA α1-4Glc(NS,6S); ∆Di-diS2, ∆HexUA(2S) α1-4GlcNS; ∆Di-triS, ∆HexUA(2S) α1-4Glc(NS,6S) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE 2 
Disaccharides composition of CS from aorta of EXTL2 KO and WT mice 
Composition  
Aorta {pmol/mg (mol %)} 
EXTL2 KO WT 
∆ DiCS-0S 138.2 ±  57.8 (18.7) 123.5 ±  50.1 (25.4) 
∆ DiCS-6S 257.9 ±  33.7 (34.8)* 121.5 ±  26.8 (25.0) 
∆ DiCS-4S 332.2 ±  112.1 (44.8) 234.3 ±  70.0 (48.2) 
∆ DiCS-diSD 12.4 ±  2.9 (1.7) 6.4 ±  1.9 (1.3) 
∆ DiCS-diSE ND ND 
∆ DiCS-TriS ND ND 
Total 740 ±  145.5 (100)* 485.7 ±  145.4 (100) 
Abbreviations:  
∆Di-0S, ∆HexUA α1-3GalNAc; ∆Di-6S, ∆HexUA α1-3GalNAc (6S); ∆Di-4S, ∆HexUA α1-3GalNAc(4S); ∆Di-diSD, 
∆HexUA(2S) α1-3GalNAc(6S); ∆Di-diSE, ∆HexUA α1-3GalNAc(4S,6S); ∆Di-triS, ∆HexUA(2S) α1-3GalNAc(4S,6S); 
ND, not detected. 
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